A patient-reported outcome measure for patients with pituitary adenoma undergoing transsphenoidal surgery
© 2022. The Author(s)..
PURPOSE: Pituitary adenomas affect patients' quality-of-life (QoL) across several domains, with long-term implications even following gross-total resection or disease remission. While clinical outcomes can assess treatment efficacy, they do not capture variations in QoL. We present the development and validation of a patient reported outcome measure (PROM) for patients with pituitary adenomas undergoing transsphenoidal surgery.
METHODS: The COSMIN checklist informed the development of the pituitary outcome score (POS). Consecutive patients undergoing surgical treatment for suspected pituitary adenoma at a single centre were included prospectively. An expert focus group and patient interviews informed item generation. Item reduction was conducted through exploratory factor analysis and expert consensus, followed by assessment of the tool's validity, reliability, responsiveness, and interpretability.
RESULTS: 96 patients with a median age of 50 years validated the POS. The final questionnaire included 25 questions with four subscales: EQ-5D-5L-QoL, Visual Symptoms, Endocrine Symptoms and Nasal Symptoms.
CONCLUSION: The POS is the first validated PROM for patients undergoing transsphenoidal surgery for a pituitary adenoma. This PROM could be integrated into contemporary practice to provide patient-centred outcomes assessment for this patient group, aligning more closely with patient objectives.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Pituitary - 25(2022), 4 vom: 15. Aug., Seite 673-683 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karvandi, Elika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 04.08.2022 Date Revised 05.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11102-022-01251-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343591642 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343591642 | ||
| 003 | DE-627 | ||
| 005 | 20231226020816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11102-022-01251-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343591642 | ||
| 035 | |a (NLM)35838913 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karvandi, Elika |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A patient-reported outcome measure for patients with pituitary adenoma undergoing transsphenoidal surgery |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.08.2022 | ||
| 500 | |a Date Revised 05.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a PURPOSE: Pituitary adenomas affect patients' quality-of-life (QoL) across several domains, with long-term implications even following gross-total resection or disease remission. While clinical outcomes can assess treatment efficacy, they do not capture variations in QoL. We present the development and validation of a patient reported outcome measure (PROM) for patients with pituitary adenomas undergoing transsphenoidal surgery | ||
| 520 | |a METHODS: The COSMIN checklist informed the development of the pituitary outcome score (POS). Consecutive patients undergoing surgical treatment for suspected pituitary adenoma at a single centre were included prospectively. An expert focus group and patient interviews informed item generation. Item reduction was conducted through exploratory factor analysis and expert consensus, followed by assessment of the tool's validity, reliability, responsiveness, and interpretability | ||
| 520 | |a RESULTS: 96 patients with a median age of 50 years validated the POS. The final questionnaire included 25 questions with four subscales: EQ-5D-5L-QoL, Visual Symptoms, Endocrine Symptoms and Nasal Symptoms | ||
| 520 | |a CONCLUSION: The POS is the first validated PROM for patients undergoing transsphenoidal surgery for a pituitary adenoma. This PROM could be integrated into contemporary practice to provide patient-centred outcomes assessment for this patient group, aligning more closely with patient objectives | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PROM | |
| 650 | 4 | |a Patient-reported outcome measure | |
| 650 | 4 | |a Pituitary adenoma | |
| 650 | 4 | |a Pituitary surgery | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a Transsphenoidal surgery | |
| 700 | 1 | |a Hanrahan, John Gerrard |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Danyal Zaman |e verfasserin |4 aut | |
| 700 | 1 | |a Boloux, Pierre-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Bremner, Fion |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrilo, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Dorward, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Grieve, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Sue |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, Glenda |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano, Inma |e verfasserin |4 aut | |
| 700 | 1 | |a Nowak, Victoria Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Kolias, Angelos |e verfasserin |4 aut | |
| 700 | 1 | |a Baldeweg, Stephanie E |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Hani Joseph |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pituitary |d 1998 |g 25(2022), 4 vom: 15. Aug., Seite 673-683 |w (DE-627)NLM097524530 |x 1573-7403 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:4 |g day:15 |g month:08 |g pages:673-683 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11102-022-01251-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 4 |b 15 |c 08 |h 673-683 | ||